Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 24(24)2023 Dec 16.
Article in English | MEDLINE | ID: mdl-38139379

ABSTRACT

Several studies have demonstrated that, beyond their antithrombotic effects, P2Y12 receptor inhibitors may provide additional off-target effects through different mechanisms. These effects range from the preservation of endothelial barrier function to the modulation of inflammation or stabilization of atherosclerotic plaques, with an impact on different cell types, including endothelial and immune cells. Many P2Y12 inhibitors have been developed, from ticlopidine, the first thienopyridine, to the more potent non-thienopyridine derivatives such as ticagrelor which may promote cardioprotective effects following myocardial infarction (MI) by inhibiting adenosine reuptake through sodium-independent equilibrative nucleoside transporter 1 (ENT1). Adenosine may affect different molecular pathways involved in cardiac fibrosis, such as the Wnt (wingless-type)/beta (ß)-catenin signaling. An early pro-fibrotic response of the epicardium and activation of cardiac fibroblasts with the involvement of Wnt1 (wingless-type family member 1)/ß-catenin, are critically required for preserving cardiac function after acute ischemic cardiac injury. This review discusses molecular signaling pathways involved in cardiac fibrosis post MI, focusing on the Wnt/ß-catenin pathway, and the off-target effect of P2Y12 receptor inhibition. A potential role of ticagrelor was speculated in the early modulation of cardiac fibrosis, thanks to its off-target effect.


Subject(s)
Myocardial Infarction , Purinergic P2Y Receptor Antagonists , Humans , Ticagrelor/pharmacology , Purinergic P2Y Receptor Antagonists/pharmacology , Purinergic P2Y Receptor Antagonists/therapeutic use , beta Catenin , Myocardial Infarction/metabolism , Adenosine , Pericardium/metabolism , Fibrosis
2.
Alzheimers Res Ther ; 14(1): 135, 2022 09 17.
Article in English | MEDLINE | ID: mdl-36115967

ABSTRACT

Aquaporin-4 (AQP4) is a channel protein that plays a fundamental role in glymphatic system, a newly described pathway for fluid exchange in the central nervous system, as well as a central figure in a fascinating new theory for the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). In this study, cerebrospinal fluid (CSF) concentration of AQP4, amyloid-ß, total tau and P-tau were determined in 103 CSF samples from patients affected by neurodegenerative dementias (AD and FTD) or psychiatric diseases and 21 controls. Significantly higher levels of AQP4 were found in AD and FTD patients compared to subjects not affected by neurodegenerative diseases, and a significant, positive correlation between AQP4 and total tau levels was found. This evidence may pave the way for future studies focused on the role of this channel protein in the clinical assessment of the glymphatic function and degree of neurodegeneration.


Subject(s)
Alzheimer Disease , Aquaporin 4 , Frontotemporal Dementia , Glymphatic System , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/metabolism , Aquaporin 4/cerebrospinal fluid , Aquaporin 4/metabolism , Frontotemporal Dementia/cerebrospinal fluid , Frontotemporal Dementia/metabolism , Glymphatic System/metabolism , Humans , Neurodegenerative Diseases/cerebrospinal fluid , Neurodegenerative Diseases/metabolism , tau Proteins/cerebrospinal fluid , tau Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...